You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: January 20, 2025

Details for Patent: 8,129,385


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 8,129,385
Title:Substituted 5-hydroxy-3,4,6,9,9a, 10-hexanhydro-2h-1-oxa04a,8a-diaza-anthracene-6,10-dioness
Abstract: The present invention is directed to a class of substituted 5-hydroxy-3,4,6,9,9a,10-hexahydro-2H-1-oxa-4a,8a-diaza-anthracene-6,10-di- ones useful as anti-HIV agents. The compounds have the formula: ##STR00001## Z.dbd.O; R.sup.20, R.sup.21, R.sup.22, R.sup.23, R.sup.24 and R.sup.25 independently are hydrogen, C.sub.1-C.sub.8 alkyl, (C.sub.6-C.sub.14)aryl-(C.sub.1-C.sub.8)alkyl, C.sub.6-C.sub.14 aryl, or alkoxy; the stereochemistry of an asymmetric carbon represented by * shows R- or S-configuration, or a mixture thereof; R.sup.X is hydrogen; R.sup.14 is hydrogen or optionally substituted lower alkyl; R.sup.3 is hydrogen; R.sup.1 is hydrogen or lower alkyl; R is halogen; and m is 1, 2 or 3; or a pharmaceutically acceptable salt thereof.
Inventor(s): Johns; Brian Alvin (Research Triangle Park, NC), Kawasuji; Takashi (Osaka, JP), Taishi; Teruhiko (Osaka, JP), Taoda; Yoshiyuki (Osaka, JP)
Assignee: Shionogi & Co., Ltd. (Osaka, JP) GlaxoSmithKline LLC (Philadelphia, PA)
Application Number:11/919,386
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 8,129,385
Patent Claim Types:
see list of patent claims
Compound; Composition;
Patent landscape, scope, and claims:

United States Patent 8,129,385: A Detailed Analysis of Scope, Claims, and Patent Landscape

Introduction to Patent 8,129,385

Patent 8,129,385 is a significant intellectual property asset that protects several pharmaceutical compounds used in the treatment of HIV. The patent was granted to Shionogi & Co., Ltd. and GlaxoSmithKline LLC on March 6, 2012, and it covers the inventions of Brian Alvin Johns, Takashi Kawasuji, Teruhiko Taishi, and Yoshiyuki Taoda [2].

Protected Drugs

The patent protects several drugs, including TIVICAY PD, TRIUMEQ PD, DOVATO, JULUCA, TIVICAY, and TRIUMEQ. These drugs are integral to the treatment of HIV and have been extended for pediatric studies with the PED designation [2].

Patent Family and International Coverage

Patent 8,129,385 has 125 patent family members across 33 countries. This extensive international coverage underscores the global significance of this patent in the pharmaceutical industry [2].

Inventors and Assignees

The inventors behind this patent are Brian Alvin Johns from Research Triangle Park, NC, and Takashi Kawasuji, Teruhiko Taishi, and Yoshiyuki Taoda from Osaka, Japan. The assignees include Shionogi & Co., Ltd. and GlaxoSmithKline LLC [1][2].

Patent Claims and Scope

The patent claims cover compound and composition aspects, specifically focusing on substituted 5-hydroxy-3,4,6,9-tetrahydro-2H-1-oxa-4a,8a-diazantracene-6,10-diones [1]. The scope of the patent is defined by its claims, which are crucial for determining the boundaries of the protected invention.

Patent Litigation and Infringement Cases

There have been notable patent infringement cases involving this patent. For instance, ViiV Healthcare Company and Shionogi & Co., Ltd. filed a lawsuit against Gilead Sciences, Inc., alleging that Gilead's HIV drug product Bictegravir infringed claims 2 and 6 of the '385 patent under the doctrine of equivalents [4][5]. This litigation highlights the competitive landscape in the pharmaceutical industry and the importance of patent protection.

Disclosure-Dedication Rule

The disclosure-dedication rule is significant in understanding the scope of this patent. This rule states that what is not claimed in a patent is dedicated to the public. Therefore, any subject matter disclosed in the written description but not claimed cannot be used as a basis for infringement [5]. This principle ensures that patentees do not extend their exclusive rights beyond what was examined by the PTO.

Patent Examination Process

The examination process for patents like 8,129,385 involves evaluating the scope of claims. Research has shown that narrower claims at publication are associated with a higher probability of grant and a shorter examination process than broader claims [3]. This indicates that the PTO tends to narrow the scope of patent claims during the examination process.

Key Takeaways

  1. Protected Drugs: TIVICAY PD, TRIUMEQ PD, DOVATO, JULUCA, TIVICAY, and TRIUMEQ.
  2. Inventors: Brian Alvin Johns (Research Triangle Park, NC), Takashi Kawasuji (Osaka, JP), Teruhiko Taishi (Osaka, JP), Yoshiyuki Taoda (Osaka, JP).
  3. Assignees: Shionogi & Co., Ltd. (Osaka, JP) and GlaxoSmithKline LLC (Philadelphia, PA).
  4. International Coverage: 125 patent family members across 33 countries.
  5. Patent Claims: Compound and composition aspects focusing on substituted 5-hydroxy-3,4,6,9-tetrahydro-2H-1-oxa-4a,8a-diazantracene-6,10-diones.
  6. Patent Litigation: Notable cases involving infringement under the doctrine of equivalents.

FAQs

  1. What drugs are protected by Patent 8,129,385?

    • TIVICAY PD, TRIUMEQ PD, DOVATO, JULUCA, TIVICAY, and TRIUMEQ [2].
  2. Who are the inventors of this patent?

    • Brian Alvin Johns (Research Triangle Park, NC), Takashi Kawasuji (Osaka, JP), Teruhiko Taishi (Osaka, JP), Yoshiyuki Taoda (Osaka, JP) [1][2].
  3. Who are the assignees of this patent?

    • Shionogi & Co., Ltd. (Osaka, JP) and GlaxoSmithKline LLC (Philadelphia, PA) [1][2].
  4. What is the significance of the disclosure-dedication rule in this context?

    • The disclosure-dedication rule ensures that what is not claimed in a patent is dedicated to the public, preventing patentees from extending their exclusive rights beyond what was examined by the PTO [5].
  5. How does the patent examination process affect the scope of claims?

    • Narrower claims at publication are associated with a higher probability of grant and a shorter examination process than broader claims [3].

Conclusion

Patent 8,129,385 is a critical intellectual property asset in the pharmaceutical industry, protecting several key drugs used in HIV treatment. The patent's extensive international coverage and significant litigation history underscore its importance. Understanding the scope and claims of this patent is essential for navigating the complex landscape of pharmaceutical patents and ensuring compliance with intellectual property laws.


Cited Information:

  1. Patent Images - United States Patent 8,129,385 [1].
  2. DrugPatentWatch - Information on drugs covered by patent 8,129,385 [2].
  3. Hoover Institution - Paper on patent claims and patent scope [3].
  4. District of Delaware - Case involving patent infringement of Bictegravir [4].
  5. District of Delaware - Memorandum opinion on patent infringement case [5].

More… ↓

⤷  Subscribe


Drugs Protected by US Patent 8,129,385

Showing 1 to 5 of 5 entries

Foreign Priority and PCT Information for Patent: 8,129,385

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Japan2005-131161Apr 28, 2005
Japan2005-312076Oct 27, 2005
PCT Information
PCT FiledApril 28, 2006PCT Application Number:PCT/US2006/016604
PCT Publication Date:November 02, 2006PCT Publication Number: WO2006/116764

International Family Members for US Patent 8,129,385

CountryPatent NumberEstimated ExpirationSupplementary Protection CertificateSPC CountrySPC Expiration
European Patent Office 1874117 ⤷  Subscribe C300676 Netherlands ⤷  Subscribe
European Patent Office 1874117 ⤷  Subscribe CA 2014 00032 Denmark ⤷  Subscribe
European Patent Office 1874117 ⤷  Subscribe PA2014021 Lithuania ⤷  Subscribe
European Patent Office 1874117 ⤷  Subscribe 1490036-9 Sweden ⤷  Subscribe
European Patent Office 1874117 ⤷  Subscribe C20140020 00130 Estonia ⤷  Subscribe
>Country>Patent Number>Estimated Expiration>Supplementary Protection Certificate>SPC Country>SPC Expiration
Showing 1 to 5 of 5 entries

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.